Company intelligence / Profile preview
Microviable Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Microviable Therapeutics develops next-generation live biotherapeutic products based on commensal human bacteria. Its lead program, MVT‑201—a cGMP-produced oral capsule representing a complete microbiota ecosystem—has shown positive preclinical results and was planned to enter clinical trials in late 2023. The company leverages its proprietary PharmaBiota® platform and a large strain collection to develop both full-microbiome and rationally designed consortia therapies targeting infectious diseases and other conditions. No published clinical trial results are available yet.
- Therapeutic areas
- OncologyGastroenterologyInfectious Diseases
- Modalities
- Live biotherapeutic products (LBPs)Complete microbiota ecosystem productsRationally defined bacterial consortia
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Microviable Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microviable Therapeutics.